Compound index

Mitochondrial-Targeted Peptides

Elamipretide

Also known as SS-31 · Forzinity

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

Evidence status & limitations

Forzinity has accelerated approval for improving muscle strength in people with Barth syndrome weighing at least 30 kg; this does not establish benefit for aging or other mitochondrial conditions.

Regulatory status

FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.

  • Forzinity · Barth Syndrome

    Improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms; accelerated approval, with confirmatory evidence required.

    Authoritative label record

Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

WADA prohibited status: current list and context

Known risks & open questions

Local reactions and hypersensitivity are documented concerns; population-specific safety and confirmatory evidence matter.

Key sources

Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.

Related compounds

  • MOTS-c

    Same scientific class · A 16-amino-acid chain. · Animal studies

Related glossary terms